The Technical Analyst
Bausch + Lomb Corporation [BLCO]
Exchange: NYSE Sector: Healthcare Industry: Medical - Instruments & Supplies
Bausch + Lomb Corporation Price, Forecast, Insider, Ratings, Fundamentals & Signals
1.15% $14.98
America/New_York / 9 mai 2024 @ 13:16
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 5 257.86 mill |
| EPS: | -0.960 |
| P/E: | -15.60 |
| Earnings Date: | Jul 31, 2024 |
| SharesOutstanding: | 350.99 mill |
| Avg Daily Volume: | 0.533 mill |
| RATING 2024-05-09 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Sell |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | 1/24 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -15.60 | sector: PE 15.43 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.37x |
| Company: PE -15.60 | industry: PE 42.42 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$25.76 (71.94%) $10.78 |
| Date: 2024-05-09 |
| Expected Trading Range (DAY) |
|---|
|
$ 14.43 - 15.61 ( +/- 3.93%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-24 | Stewart Andrew J. | Sell | 3 943 | Common Shares, No Par Value |
| 2024-04-24 | Bailey A Robert D | Sell | 9 838 | Common Shares, No Par Value |
| 2024-03-29 | Robertson Russel C | Buy | 1 481 | Common Shares, No Par Value |
| 2024-03-29 | Paulson John | Buy | 1 264 | Common Shares, No Par Value |
| 2024-03-29 | De Schutter Richard U | Buy | 1 553 | Common Shares, No Par Value |
| INSIDER POWER |
|---|
| -7.62 |
| Last 94 transactions |
| Buy: 2 803 512 | Sell: 8 839 600 |
Forecast:
14:54 - $14.99
Live Trading Signals (every 1 min)
Forecast
1: 13:24 - $15.03
Forecast 2: 14:14 - $14.98
Forecast 3: 14:54 - $14.99
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $14.98 (1.15% ) |
| Volume | 0.314 mill |
| Avg. Vol. | 0.533 mill |
| % of Avg. Vol | 59.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BLCO
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
BLCO
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
Latest Press Releases
2024-05-01 06:58:00 - Press Release
Bausch + Lomb Announces First-quarter 2024 Results
Vaughan, ontario--(business wire)--bausch + lomb corporation (nyse/tsx: blco), a leading global eye health company dedicated to helping people see better to live better, today announced its first-quarter 2024 financial results. “outperformance from each of our business units and solid results across geographies led to an impressive quarter and once again demonstrated our quality of growth,” said brent saunders, chairman and ceo, bausch + lomb. “our key franchises continue to deliver, and a focu.
2024-04-29 07:00:00 - Press Release
Bausch + Lomb Announces Presentation Of New Data At The Association For Research In Vision And Ophthalmology Annual Meeting
Vaughan, ontario--(business wire)--bausch + lomb corporation (nyse/tsx: blco), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of 21 scientific poster presentations during the association for research in vision and ophthalmology annual meeting, which will take place in seattle may 5-9, 2024. the posters highlight the results of studies evaluating consumer, pharmaceutical, surgical and vision care products from the compa.
2024-04-25 08:30:00 - Press Release
Bausch + Lomb Announces Statistically Significant Results From A Clinical Study Of A Novel Daily Nutritional Supplement For Dry Eyes
Vaughan, ontario--(business wire)--bausch + lomb corporation (nyse/tsx: blco), a leading global eye health company dedicated to helping people see better to live better, today announced frontiers in ophthalmology published statistically significant results from a clinical study evaluating the efficacy and safety of a novel daily nutritional supplement formulated to address the symptoms of dry eyes.1 bausch + lomb expects to launch the supplement, which features a proprietary blend of ingredient.
2024-04-18 07:00:00 - Press Release
Bausch + Lomb Reports More Than 84 Million Units Of Contact Lenses, Lens Care And Eye Care Materials Collected Through Innovative Recycling Programs
Vaughan, ontario--(business wire)--bausch + lomb corporation (nyse/tsx: blco), a leading global eye health company dedicated to helping people see better to live better, today announced its one by one and biotrue® eye care recycling programs have collected 84,343,540 units, or 510,116 pounds, of used contact lenses, eye care and lens care materials in the u.s., which is greater than the weight of the statue of liberty.1 “eye care professionals, patients and consumers have helped us collect hund.
2024-04-15 12:00:00 - Press Release
Bausch + Lomb Will Release First-quarter 2024 Financial Results On May 1
Vaughan, ontario--(business wire)--bausch + lomb corporation (nyse/tsx: blco), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on wednesday, may 1, 2024. bausch + lomb will host a conference call and live webcast at 8 a.m. et to discuss the results and provide a business update. all materials will be made available on the investor relations section of the bausch + lomb website prior to the start of.
Latest News
2024-04-15 12:00:00 - Business Wire
Bausch + Lomb Will Release First-Quarter 2024 Financial Results on May 1
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter 2024 financial results on Wednesday, May 1, 2024. Bausch + Lomb will host a conference call and live webcast at 8 a.m. ET to discuss the results and provide a business update. All materials will be made available on the Investor Relations section of the Bausch + Lomb website prior to the start of.
2024-04-08 12:41:27 - Zacks Investment Research
BLCO vs. AVTR: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks is more attractive to value investors?
2024-03-25 13:01:04 - Zacks Investment Research
All You Need to Know About Bausch + Lomb (BLCO) Rating Upgrade to Buy
Bausch + Lomb (BLCO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2024-03-21 12:41:07 - Zacks Investment Research
BLCO or AVTR: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks offers value investors a better bang for their buck right now?
2024-03-20 13:21:04 - Zacks Investment Research
Surging Earnings Estimates Signal Upside for Bausch + Lomb (BLCO) Stock
Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
2024-02-21 13:07:09 - Seeking Alpha
Bausch + Lomb Corporation (BLCO) Q4 2023 Earnings Call Transcript
2024-02-21 10:31:27 - Zacks Investment Research
Compared to Estimates, Bausch + Lomb (BLCO) Q4 Earnings: A Look at Key Metrics
Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
2024-02-21 08:27:00 - Market Watch
Bausch & Lomb's stock soars 11% after earnings beat
Bausch + Lomb Corp.'s stock soared 10% early Wednesday, after the vision-care company's adjusted fourth-quarter profit topped estimates and it offered upbeat revenue guidance for 2024.
2024-02-15 10:20:39 - Zacks Investment Research
Seeking Clues to Bausch + Lomb (BLCO) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Bausch + Lomb (BLCO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
2024-02-14 13:11:05 - Zacks Investment Research
Will Bausch + Lomb (BLCO) Beat Estimates Again in Its Next Earnings Report?
Bausch + Lomb (BLCO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.